Matbaline D 75/20 Capsule DR is a combination pharmaceutical formulation containing Pregabalin 75 mg and Duloxetine 20 mg, designed for the management of neuropathic pain and associated depressive symptoms. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channel function to reduce neurotransmitter release, thereby alleviating neuropathic pain and seizures. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), enhances central nervous system neurotransmitter levels, contributing to improved mood and pain modulation. The delayed-release (DR) capsule ensures gradual absorption, optimizing therapeutic efficacy and minimizing gastrointestinal side effects. Matbaline D is indicated for conditions such as diabetic peripheral neuropathy, fibromyalgia, generalized anxiety disorder, and major depressive disorder with concomitant neuropathic pain. The combination therapy addresses both pain and mood disorders, providing a comprehensive approach to patient care. Common adverse effects may include dizziness, somnolence, dry mouth, nausea, and constipation. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of serotonin syndrome. Matbaline D 75/20 Capsule DR should be prescribed and monitored by healthcare professionals, with dosage adjustments tailored to individual patient response and tolerability. It is contraindicated in patients with hypersensitivity to either component or concurrent monoamine oxidase inhibitor therapy.